← Evidence map

ReviewCancers2026

Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates.

Baha Sharaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates. | OpenQuestion